Topline data expected as early as Q1 2024OCALA, Fla., Aug. 08, 2023 AIM ImmunoTech Inc. today announced the completion of enrollment in the company’s Phase 2 study evaluating Ampligen® as a.
AIM ImmunoTech Inc.: AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Preliminary Ampligen data demonstrates potential to be an effective treatment option for post-COVID conditions Enrollment expected to be completed in Q4 2023 OCALA, Fla., July 10, 2023 .
AIM ImmunoTech Inc.: AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin a Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatm finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.